Bausch Health [BHC] vs Alkermes plc [ALKS] Detailed Stock Comparison
Bausch Health
NYSE
Loading...
Alkermes plc
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Bausch Health wins in 8 metrics, Alkermes plc wins in 10 metrics, with 0 ties. Alkermes plc appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Bausch Health | Alkermes plc | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 28.85 | 14.04 | Alkermes plc |
| Price-to-Book Ratio | N/A | 2.95 | N/A |
| Debt-to-Equity Ratio | 14,787.76 | 4.47 | Alkermes plc |
| PEG Ratio | 1.70 | -7.58 | Alkermes plc |
| EV/EBITDA | 7.62 | 9.56 | Bausch Health |
| Profit Margin (TTM) | 0.99% | 23.15% | Alkermes plc |
| Operating Margin (TTM) | 18.02% | 23.80% | Alkermes plc |
| EBITDA Margin (TTM) | 18.02% | 23.80% | Alkermes plc |
| Return on Equity | 14.29% | 23.94% | Alkermes plc |
| Return on Assets (TTM) | 4.35% | 10.49% | Alkermes plc |
| Free Cash Flow (TTM) | $1.26B | $405.64M | Bausch Health |
| 1-Year Return | 27.60% | 6.51% | Bausch Health |
| Price-to-Sales Ratio (TTM) | 0.28 | 3.19 | Bausch Health |
| Enterprise Value | $23.70B | $3.85B | Bausch Health |
| EV/Revenue Ratio | 2.40 | 2.56 | Bausch Health |
| Gross Profit Margin (TTM) | 69.80% | 87.34% | Alkermes plc |
| Revenue per Share (TTM) | $27 | $9 | Bausch Health |
| Earnings per Share (Diluted) | $0.26 | $2.07 | Alkermes plc |
| Beta (Stock Volatility) | 0.41 | 0.43 | Bausch Health |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Bausch Health vs Alkermes plc Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Bausch Health | -0.13% | -10.19% | 15.05% | 66.44% | 4.46% | -5.67% |
| Alkermes plc | 2.37% | 2.41% | 10.06% | -1.00% | -16.24% | 3.48% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Bausch Health | 27.60% | 44.59% | -55.71% | -96.83% | -67.70% | -57.73% |
| Alkermes plc | 6.51% | 21.31% | 82.08% | -52.86% | 117.14% | 72.28% |
Performance & Financial Health Analysis: Bausch Health vs Alkermes plc
| Metric | BHC | ALKS |
|---|---|---|
| Market Information | ||
| Market Cap | $2.78B | $4.80B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 7,324,500 | 1,310,810 |
| 90 Day Avg. Volume | 3,405,347 | 1,876,863 |
| Last Close | $7.49 | $29.75 |
| 52 Week Range | $4.25 - $9.85 | $25.56 - $36.45 |
| % from 52W High | -23.96% | -18.38% |
| All-Time High | $263.81 (Aug 03, 2015) | $98.50 (Feb 28, 2000) |
| % from All-Time High | -97.16% | -69.80% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.05% | -0.02% |
| Quarterly Earnings Growth | 13.80% | -0.05% |
| Financial Health | ||
| Profit Margin (TTM) | 0.01% | 0.23% |
| Operating Margin (TTM) | 0.18% | 0.24% |
| Return on Equity (TTM) | 0.14% | 0.24% |
| Debt to Equity (MRQ) | 14,787.76 | 4.47 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-2.07 | $9.84 |
| Cash per Share (MRQ) | $4.67 | $6.15 |
| Operating Cash Flow (TTM) | $1.51B | $521.00M |
| Levered Free Cash Flow (TTM) | $1.35B | $345.67M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | $0.00 | N/A |
Valuation & Enterprise Metrics Analysis: Bausch Health vs Alkermes plc
| Metric | BHC | ALKS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 28.85 | 14.04 |
| Forward P/E | 1.70 | 14.46 |
| PEG Ratio | 1.70 | -7.58 |
| Price to Sales (TTM) | 0.28 | 3.19 |
| Price to Book (MRQ) | N/A | 2.95 |
| Market Capitalization | ||
| Market Capitalization | $2.78B | $4.80B |
| Enterprise Value | $23.70B | $3.85B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.40 | 2.56 |
| Enterprise to EBITDA | 7.62 | 9.56 |
| Risk & Other Metrics | ||
| Beta | 0.41 | 0.43 |
| Book Value per Share (MRQ) | $-2.07 | $9.84 |
Financial Statements Comparison: Bausch Health vs Alkermes plc
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BHC | ALKS |
|---|---|---|
| Revenue/Sales | $2.53B | $306.51M |
| Cost of Goods Sold | $764.00M | $49.20M |
| Gross Profit | $1.77B | $257.31M |
| Research & Development | $159.00M | $71.82M |
| Operating Income (EBIT) | $457.00M | $13.79M |
| EBITDA | $776.00M | $32.91M |
| Pre-Tax Income | $140.00M | $25.49M |
| Income Tax | $12.00M | $3.03M |
| Net Income (Profit) | $128.00M | $22.46M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BHC | ALKS |
|---|---|---|
| Cash & Equivalents | $1.13B | $399.81M |
| Total Current Assets | $5.73B | $1.48B |
| Total Current Liabilities | $4.26B | $443.73M |
| Long-Term Debt | $21.23B | $67.81M |
| Total Shareholders Equity | $-240.00M | $1.51B |
| Retained Earnings | $-9.88B | $-953.99M |
| Property, Plant & Equipment | N/A | $82.41M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BHC | ALKS |
|---|---|---|
| Operating Cash Flow | $236.00M | $122.31M |
| Capital Expenditures | $-115.00M | $-8.40M |
| Free Cash Flow | $87.00M | $88.70M |
| Debt Repayment | $-168.00M | $0 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | BHC | ALKS |
|---|---|---|
| Shares Short | 7.29M | 13.82M |
| Short Ratio | 4.58 | 6.35 |
| Short % of Float | 0.02% | 0.12% |
| Average Daily Volume (10 Day) | 7,324,500 | 1,310,810 |
| Average Daily Volume (90 Day) | 3,405,347 | 1,876,863 |
| Shares Outstanding | 367.84M | 162.18M |
| Float Shares | 187.72M | 162.42M |
| % Held by Insiders | 0.11% | 0.01% |
| % Held by Institutions | 0.69% | 1.05% |
Dividend Analysis & Yield Comparison: Bausch Health vs Alkermes plc
| Metric | BHC | ALKS |
|---|---|---|
| Last 12-Month Dividend | $0.00 | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | $0.00 | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | $0.00 | N/A |
| Ex-Dividend Date | N/A | N/A |